1st World Congress on Gallium-68 and Peptide Receptor Radio Nuclide Therapy (PRRNT) THERANOSTICS – on the Way to Personalized Medicine
June 23 – 26, 2011

ORGANIZED BY
Prof. Dr. med. Richard P. Baum, Dept. of Nuclear Medicine – Center for PET/CT, Zentralklinik Bad Berka, Germany
Prof. Dr. sc. nat. Frank Rösch, Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Germany
Welcome Message

Dear Colleagues:

Since the decoding of the human genome a decade ago, medicine is rapidly moving toward a preventive and personalized mode focused on genetic and molecular diagnostics and targeted, individualized therapies. THERANOSTICS is the emerging field of molecular targeting of vectors which can be used for both therapies and diagnosis, when modified accordingly. This term was specifically used in the context of certain radiopharmaceuticals, so that the same pharmaceutical (e.g., a peptide) when labeled with a positron emitter, can be used for diagnosis using PET/CT, and when labeled with a beta emitter, may be used for therapy of a particular disease, targeted specifically by that radiopharmaceutical. The importance of THERANOSTICS is that it takes into account personalized management of disease. THERANOSTICS embodies both molecular and personalized medicine.

New

• Self-shielded – no hot cell required
• Outstanding price-performance ratio
• Sterile single-use kits
• Filter integrity test
• Personalized on-site customer service

ITG Isotope Technologies Garching GmbH
Lichtenbergstraße 1 . 85748 Garching . Germany
Phone +49 89 289-13908 . Fax +49 89 289-13929
sales@itg-garching.de . www.itg-garching.de

Notice Not for human use - All rights reserved

The 1st World Congress on Gallium-68 and Peptide Receptor Radiopharmaceutical Therapy (PRRNT) is co-organized by the Department of Nuclear Medicine/PET Center, Zentralklinik Bad Berka and the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. Target audience include chemists, physicians, and investigators dealing with generators, PET radiochemistry as well as molecular imaging and radionuclide therapy.

The congress plans to both educate and to offer a unique forum for high level scientific discussions on the recent developments in the exciting field of THERANOSTICS. A special focus is the rapidly developing research and clinical application of Ga-68 and other generator-produced PET radioisotopes, new PET radiopharmaceuticals as well as PRRNT.

iQS® Ga-68 Fluidic Labeling Module

NEW
For Ga-68 radiopharmaceutical chemistry, this World Congress intends to reflect the first decade of the renaissance of Ge-68/Ga-68 radionuclide generators. The last 10 years of commercially available ionic generators have stimulated both systematic chemical research and clinical applications of promising tracers. Outstanding speakers from all over the world will be giving their fascinating insights into their research and clinical work, creating new ideas and concepts on the way to personalized medicine. Within the next decade, further and rapid developments may be expected.

A considerable number of companies are participating in the Trade Exhibition, presenting the latest technological developments in generator technology and Ga-68 modules, devices and labeling strategies. In addition, a “Hands-on Training Course” on Ge-68/Ga-68 generators, for learning the practical principles of Ge-68/Ga-68 radionuclide generator elution for all types of today’s available commercial systems, for eluate post-processing and Ga-68 labeling procedures as well as for product purification, combined with those of analogue Y-90 and Lu-177 chemistry, is offered (for a limited number of participants) on June 27-28, 2011 at the Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany. In addition, this Training Course – as well as the World Congress itself, realizes the idea of transferring novel technologies to the member states of the IAEA, thus contributing to the concept of translating Ge-68/Ga-68 generators and PPRNT all over the world.

Looking forward to seeing you in Bad Berka!

Prof. Dr. med. Richard P. Baum
Prof. Dr. sc. nat Frank Rösch

In collaboration with / under the auspices of

[Logos of IAEA, EANM, SNM, irist]
Congress Venue

Kultur- und Kongresshaus »Station 33«
Zentralklinik Bad Berka GmbH
Robert-Koch-Allee 9
99437 Bad Berka, Germany

website: www.zentralklinik.de

Registration, Accomodation, Social Events and Trade Exhibition

KONGRESS- UND KULTURMANAGEMENT GMBH
Karl-Liebknecht-Str. 17-21
99423 Weimar, Germany

fon: +49 3643 2468-0
fax: +49 3643 2468-31
E-MAIL: linda.schmidt@kukm.de
E-MAIL: stephan.weitz@kukm.de
website: www.kukm.de

Local Organizing Committee

→ Harshad Kulkarni, Bad Berka (Germany)
→ Julitta Rück-Baum, Bad Berka (Germany)
→ Cecilia Carreras, Bad Berka (Germany)
→ Jorge Schalch, Bad Berka (Germany)
→ Sabine Seifert, Bad Berka (Germany)

Registration desk will be open:
Thursday June 23, 2011 17:00 pm – 19:00 pm
Friday June 24, 2011 07:30 am – 18:00 pm
Saturday June, 25, 2011 07:30 am – 18:00 pm
Sunday June 26, 2011 08:00 am – 15:00 pm

The Landesärztekammer Thüringen designates this 1st World Congress on Gallium-68 and Peptide Receptor Radionuclide Therapy (PRRNT) for a maximum of 23 CME credits (Category A).

Bus shuttle services to the Zentralklinik Bad Berka (Congress Center »Station 33«) will be announced.
Scientific Committee

Chair:
- Richard P. Baum, Bad Berka (Germany)
- Frank Rösch, Mainz (Germany)

Local Scientific Committee:
- Dieter Hörsch, Bad Berka (Germany)
- Marten Hommann, Bad Berka (Germany)
- Daniel Kämerer, Bad Berka (Germany)
- Harshad Kulkarni, Bad Berka (Germany)
- Alexander Petrovich, Bad Berka (Germany)

International Scientific Committee:
- Adil Al-Nahhas, London (United Kingdom)
- Abas Alavi, Philadelphia (USA)
- Horacio Amaral, Santiago de Chile (Chile)
- Carolyn J. Anderson, Pittsburgh (USA)
- Martin Anlauf, Duesseldorf (Germany)
- Rudolf Arnold, Munich (Germany)
- Chandra Sekhar Bai, Delhi (India)
- Emerita Barrenechea, Manila (Philippines)
- Peter Bartenstein, Munich (Germany)
- Otakar Bholiahovek, Prague (Czech Republic)
- Aron Belfer, Sao Paulo (Brasil)
- Thomas Beyer, Tubingen (Germany)
- Gerd Binnig, Munich (Germany)
- Hans-Jürgen Biersack, Bonn (Germany)
- Bozena Birkenfeld, Szczecin (Poland)
- Lisa Bodei, Milano (Italy)
- Otto Boerman, Nijmegen (The Netherlands)
- Emilio Bombarderi, Milano (Italy)
- Stefano Boschi, Bologna (Italy)
- Patrick Bouret, Rennes (France)
- Wouter Breeman, Rotterdam (The Netherlands)
- John Buscombe, Cambridge (United Kingdom)
- Jorge Carrasquillo, New York (USA)
- Ignasi Carrió, Barcelona (Spain)
- Arturo Chiti, Rozzano (Italy)
- June-Key Chung, Seoul (South Korea)
- Cathy Cutler, Columbia (USA)
- Jaroslav Cwikla, Warsaw (Poland)
- Johannes Czernin, Los Angeles (USA)
- Clemens Decristoforo, Innsbruck (Austria)
- Dominique Delbeke, Nashville (USA)
- Marion de Jong, Rotterdam (The Netherlands)
- Enrique Estrada Lobato, Mexico City (Mexico)
- Samer Ezzidin, Bonn (Germany)
- Stefano Fantini, Bologna (Italy)
- Patrick Flameng, Bruselles (Belgium)
- Flavio Forrer, Basel (Switzerland)
- Savvas Frangos, Nicosia (Cyprus)
- Michael Gabriel, Linz (Austria)
- Michael Graham, Iowa City (USA)
- Frank Grünwald, Frankfurt/Main (Germany)
- Uday Bhonsle, IAEA, Vienna (Austria)
- Rodney Hicks, Melbourne (Australia)
- Alicja Hubalewska-Dydejczyk, Krakow (Poland)
- Jae Min Jeong, Seoul (South Korea)
- Kaley Kairemo, Helsinki (Finland)
- Andrew S. Kennedy, Cary (USA)
- E. Edmund Kim, Houston (USA)
- Günter Klöppel, Munich (Germany)
F. F. (Russ) Knapp, Oakridge (USA)
Wolfram Knapp, Hannover (Germany)
Jörg Kotzerke, Dresden (Germany)
Bernd J. Krause, Rostock (Germany)
Eric Krenning, Rotterdam (The Netherlands)
Vijay Kumar, Sydney (Australia)
Rakesh Kumar, New Delhi (India)
Jolanta Kunikowska, Warsaw (Poland)
Dik Kwakkelboom, Rotterdam (The Netherlands)
Werner Langsteger, Linz (Austria)
Bengt Langström, Uppsala (Sweden)
Michael Lassmann, Wuerzburg (Germany)
Myung-Chul Lee, Seoul (South Korea)
Vikram Lele, Mumbai (India)
Eric H. Liu, Nashville (USA)
Carlos Lihbaber, Cape Town (South Africa)
H. Jürgen Machulla, Ulm (Germany)
Helmut Mäcke, Freiburg (Germany)
Umar Mahmood, Boston (USA)
J. (Sandy) McEwan, Edmonton (Canada)
Theodossia Maina, Athens (Greece)
Arun Malhotra, New Delhi (India)
Geerd-J. Meyer, Hannover (Germany)
Jasna Mihailovic, Sremska Kamenica (Serbia)
Jung-Joon Min, Gwangju (South Korea)
B. R. Mittal, Chandigarh (India)
Irvin M. Modlin, New Haven (USA)
Luç Moertelmans, Leuven (Belgium)
Jan Müller-Brand, Basel (Switzerland)
Sue O’Dorso, Iowa City (USA)
Juan P. Oliva, Habana (Cuba)
Wim J. Oyen, Nijmegen (The Netherlands)
Ajit Kumar Padhy, Singapore
Giovanni Paganelli, Milano (Italy)
Stan Pauwels, Leuven (Belgium)
Alan Perkins, Nottingham (United Kingdom)
Gabriele Pöpperl, Stuttgart (Germany)
Vikas Prasad, Berlin (Germany)
Jean-Claude Reubi, Bern (Switzerland)
Mike Sathekge, Pretoria (South Africa)
Maung Maung Saw, Singapore
Heinrich Schelbert, Los Angeles (USA)
Michael K. Schultz, Iowa City (USA)
Manisha H. Shah, Columbia (USA)
Alberto Signore, Roma (Italy)
Baliinder Singh, Chandigarh (India)
Victoria Soroa, Buenos Aires (Argentina)
Suresh Srivastava, Brookhaven (USA)
Ludwig G. Strauss, Heidelberg (Germany)
Jonathan R. Strosberg, Tampa (USA)
Anders Sundin, Stockholm (Sweden)
Jean-Noel Talbot, Paris (France)
David M. Townsand, Singapore
J. Harvey Turner, Fremantle (Australia)
Henry F. VanBrocklin, San Francisco (USA)
Alfons Verbruggen, Leuven (Belgium)
Irene Virgolini, Innsbruck (Austria)
Richard Wahl, Baltimore (USA)
Wolfgang Weber, Freiburg (Germany)
Hans-Jürgen Wester, Munich (Germany)
Gregory Wiseman, Rochester (USA)
Damian Wild, Freiburg (Germany)
Edward M. Wolin, Los Angeles (USA)
Eugene A. Woltering, New Orleans (USA)
John Zaknun, IAEA, Vienna (Austria)
Konstantin Zernosekov, Bern (Switzerland)
Invited Moderators and Speakers

- Tim Akhurst, Melbourne (Australia)
- Horacio Amaral, Santiago de Chile (Chile)
- Chandra Sekhar Bal, Delhi (India)
- Thomas Beyer, Zurich (Switzerland)
- Hans-Jürgen Biersack, Bonn (Germany)
- Lisa Boedi, Milano (Italy)
- Otto Boerman, Nijmegen (The Netherlands)
- Stefano Boschi, Bologna (Italy)
- Wouter Breeman, Rotterdam (The Netherlands)
- John Buscombe, Cambridge (United Kingdom)
- Ignasi Carrió, Barcelona (Spain)
- Cathy Cutler, Columbia (USA)
- Jaroslaw Cwikla, Warsaw (Poland)
- Marion de Jong, Rotterdam (The Netherlands)
- Annare Elman, Cape Town (South Africa)
- Enrique Estrada Lobato, Mexico City (Mexico)
- Samer Ezzidin, Bonn (Germany)
- Marco Fellner, Mainz (Germany)
- Marc Harfensteller, Munich (Germany)
- Dieter Hörsch, Bad Berka (Germany)
- Jae Min Jeong, Seoul (South Korea)
- Daniel Kämmerer, Bad Berka (Germany)
- Kaveh Kairemo, Helsinki (Finland)
- Wolfram Knapp, Hannover (Germany)
- Jörg Kotzerke, Dresden (Germany)
- Vijay Kumar, Sydney (Australia)
- Rakesh Kumar, New Delhi (India)
- Jolanta Kunikowska, Warsaw (Poland)
- Clemens Kratochwil, Heidelberg (Germany)
- Dik Kwakkeboom, Rotterdam (The Netherlands)
- Bengt Langström, Uppsala (Sweden)
- Michael Lassmann, Wuerzburg (Germany)
- Vikram Lele, Mumbai (India)
- Eric H. Liu, Nashville (USA)
- Carlos Libhaber, Cape Town (South Africa)
- Helmut Mäcke, Freiburg (Germany)
- Theodosia Maina, Athens (Greece)
- Geerd-Jürgen Meyer, Hannover (Germany)
- Jung-Joon Min, Gwangju (South Korea)
- Jan Müller-Brand, Basel (Switzerland)
- Sue O’Dorisio, Iowa City (USA)
- Tom O’Dorisio, Iowa City (USA)
- Aijit Kumar Padhy, Singapore
- Alexander Petrovich, Bad Berka (Germany)
- Gabriele Pöppler, Stuttgart (Germany)
- Vikas Prasad, Berlin (Germany)
- Jean-Claude Reubi, Bern (Switzerland)
- Arndt Rimpler, Berlin (Germany)
- Maung Maung Saw, Singapore
- Christiane Schuchardt, Bad Berka (Germany)
- Michael K. Schultz, Iowa City (USA)
- Baljinder Singh, Chandigarh (India)
- Jean-Noel Talbot, Paris (France)
- Oliver Thews, Halle (Germany)
- J. Harvey Turner, Fremantle (Australia)
- Henry F. VanBrocklin, San Francisco (USA)
- Alfons Verbruggen, Leuven (Belgium)
- Irene Virgolini, Innsbruck (Austria)
- Stephan Walrand, Brussels (Belgium)
- Wolfgang Weber, Freiburg (Germany)
- Damian Wild, Freiburg (Germany)
- Edward M. Wolin, Los Angeles (USA)
- Konstantin Zhernosekov, Bern (Switzerland)
Thursday, June 23, 2011 – Pre-Congress Symposium

Molecular Imaging and Treatment Options in NET Patients

14:00 Clinical Value of Ga-68 Imaging  V. Prasad (Berlin, Germany)
14:20 Ga-68 Labeling–Generators & Synthesis Modules  K. Zhernosekov (Villigen, Switzerland)
14:40 ITG iQS® Ga-68 Fluidic Labeling Module  J. Jernström (Garching, Germany)

Coffee Break

15:10 Treatment Options for NET Patients  D. Hörsch (Bad Berka, Germany)
15:30 Multimodality Radiopeptide Therapy of NET  J.H. Turner (Fremantle, Australia)
15:50 Challenges in Production of Therapeutic Isotopes  M. Harfensteller (Garching, Germany)

Location:
Zentralklinik Bad Berka – Lecture Hall
(Hörsaal, 1st floor at main entrance of the hospital)
Robert-Koch-Allee 9, 99437 Bad Berka, Germany
Friday, June 24, 2011 – Scientific Programme

07:30 Registration (also possible on Thursday, 17–19 hrs p.m.)

08:15 Opening Ceremony
Chairpersons: Richard P. Baum, Bad Berka (Germany); Frank Rösch, Mainz (Germany)
Opening Remarks

→ Local Representatives (Zentralklinik Bad Berka, Rhön-Klinikum AG)  
  Martin Bosch, Norbert Presselt
→ International Atomic Energy Agency (IAEA)  
  Uday Bhonsle
→ World Federation of Nuclear Medicine and Biology (WFNMB)  
  Enrique Estrada Lobato
→ World Association for Radionuclide and Molecular Therapy (WARMTH)  
  Ajit Kumar Padhy
→ European Association of Nuclear Medicine (EANM)  
  Wolfram H. Knapp
→ Center for Molecular Imaging Innovation and Translation (CMiITT)  
  Henry Van Broecklin
→ Deutsche Gesellschaft für Nuklearmedizin (DGN)  
  Hans-Jürgen Biersack

Opening Lecture

08:41 Ge-68/Ga-68 Generators – Past, Present and Future  
  Frank Rösch, Mainz (Germany)

09:30 – 10:00 Coffee/Tea/Opening of Trade Exhibition/Poster Viewing

10:00 – 11:20 SCIENTIFIC SESSION 1
Ge-68/Ga-68 Generators, Post-processing and Modules
Chairpersons: Bengt Langström, Uppsala (Sweden); Richard P. Baum, Bad Berka (Germany)

10:00 O-02 Pro and Cons – Some Thoughts Around Technology for Routine Production of Ga-68 Tracers  
  Bengt Langström, Uppsala (Sweden)

10:20 O-03 Overview and Perspectives on Automation Strategies in Ga-68 Radiopharmaceutical Production  
  Stefano Boschi, Bologna (Italy)

10:40 O-04 Post-processing via Cation Exchange Cartridges: Versatile Options  
  Frank Rösch, Mainz (Germany)

Free Oral Papers

11:00 O-05 Automated Preparation Method for Ga-68 DOTATATE Using Anion-exchange Prepurification of the Ge-68/Ga-68 Generator Eluate  
  Geerd-J. Meyer, Hannover (Germany)

11:10 O-06 Ge-68/Ga-68 Labeling System for Efficient and Cost Effective Labeling of Radiopharmaceuticals  
  Jussi Jernstroem, Munich (Germany)
Friday, June 24, 2011 – Scientific Programme

11:20 – 12:30 SCIENTIFIC SESSION 2
Gallium Chemistry: Ligands
Chairpersons: Clemens Decristoforo, Innsbruck (Austria); Helmut Mäcke, Freiburg (Germany)

11:20 O-07 Gallium-68 Labeled Annexin for Apoptosis Imaging
Alfons Verbruggen, Leuven (Belgium)

11:40 O-08 Ga-68 PET for Infection Imaging, Inflammation and Other Indications
Vijay Kumar, Sydney (Australia)

12:00 O-09 Development of Ga-68 Labeled Amino Acids and Nitroimidazole Derivatives
Jae Min Jeong, Seoul (South Korea)

Free Oral Papers

12:10 O-10 PET Imaging Using Ga-68 Labeled Somatostatin Antagonists is Influenced by the Choice of the Chelator
Melpomeni Fani, Freiburg (Germany)

12:20 O-11 A Novel Ga-68 Labeled Pteroic Acid-based PET Tracer for Tumor Imaging via the Folate Receptor
Berit Kühle, Mainz (Germany)

12:30 – 14:00 Lunch/Visit of Trade Exhibition / Poster Viewing

14:00 – 15:10 SCIENTIFIC SESSION 3
Gallium Chemistry: Peptidic Tracers
Chairpersons: Otto C. Boerman, Nijmegen (The Netherlands); Alfons Verbruggen, Leuven (Belgium)

14:00 O-12 Ga-68 Labeled Peptides Targeting G-protein Coupled Receptors: Agonists versus Antagonists
Helmut Mäcke, Freiburg (Germany)

14:20 O-13 Ga-68 Labeled Nanoparticles, Peptides and Phage Display Selected Peptides for PET Imaging of Cancer
Cathy Cutler, Columbia (USA)

Free Oral Papers

14:40 O-14 Molecular Imaging of HER2 Expression in Breast Cancer Using Ga-68-NOTA Anti-HER2 Nanobodies
Catarina Xavier, Brussels (Belgium)

14:50 O-15 Radiolabeling and Biodistribution of Ga-68-AMBA in ZR75-1 Human Breast Cancer Tumors
Aureli Pignon, Paris (France)

15:00 O-16 Design, Synthesis and Preclinical Evaluation of Ga(III)-DOTA-modified Ranatensin Analogues for SPECT/PET Imaging
Anil K. Mishra, Delhi (India)
Friday, June 24, 2011 – Scientific Programme

15:10 – 16:30 SCIENTIFIC SESSION 4
New Ga-68 Pharmaceuticals: Chemistry and Pre-clinical Evaluation
Chairpersons: Cathy Cutter, Columbia (USA); Geerd-J. Meyer, Hannover (Germany)

15:10 O-17 Pretargeted Immuno-PET of Colorectal Cancer with Bispecific Antibodies
Otto C. Boerman, Nijmegen (The Netherlands)

15:30 O-18 Ga-68 Labeled PET Tracers for Studying Pathophysiological Properties of the P-glycoprotein
Oliver Thews, Halle (Germany)

15:50 O-19 Click Cyclized Ga-68 Labeled alpha MSH Peptides for Imaging Medulloblastoma
Michael K. Schultz, Iowa City (USA)

16:10 Free Oral Papers

16:10 O-20 In vivo Comparison of Ga-68 and In-111 labeled Affibody Molecule Analogues
Inna Velikyan, Uppsala (Sweden)

16:20 O-21 Novel DOTA-Neurotensin Analogue and Ga-68 PET Imaging of Neurotensin Receptor-positive Tumors in Mice
Anne Gruaz-Guyon, Paris (France)

16:30 – 17:00 Coffee/Tea/Visit of Trade Exhibition / Poster Viewing

17:00 – 18:30 SCIENTIFIC SESSION 5
Lu-177, Y-90: Production, Chemistry and Pre-clinical Evaluation
Chairpersons: Konstantin Zhemsekov, Bern (Switzerland); Maung Maung Saw, Singapore

17:00 O-22 Radiometals for Therapeutic Application: Availability and Future Prospects
Marc Harfensteller, Munich (Germany)

17:20 O-23 Lu-177-BPAMD and Ga-68-BPAMD: THERANOSTICS for Bone Metastases
Marco Fellner, Mainz (Germany)

17:40 O-24 Radiolabeled GRPR-Antagonists: New Promising Tools for the Diagnosis and Therapy of GRPR-positive Tumors
Theodosia Maina, Athens (Greece)

Free Oral Papers

18:00 O-25 Lu-177/Y-90 - Intermediate Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation
Denis R. Beckford Vera, Rez (Czech Republic)

18:10 O-26 Automated and cGMP-consistent Synthesis of Lu-177 and Ga-68 Labeled Peptides Clemsen Decri forfeiture, Innsbruck (Austria)

18:20 End of Sessions
18:45 Busses Leaving from Zentralklinik Bad Berka to Schloss Ettersburg
19:30 Welcome Reception at Schloss Ettersburg
Saturday, June 25, 2011 – Scientific Programme

07:30 Registration

08:00 – 10:00 SCIENTIFIC SESSION 6
Ga-68 Imaging in Clinical Practice – Worldwide Experience
Chairpersons: Wolfram H. Knapp, Hannover (Germany); Wolfgang Weber, Freiburg (Germany)

08:00 O-27 The European Experience
Gabriele Pöpperl, Stuttgart (Germany)

08:15 O-28 The Indian Experience
Vikram Lele, New Delhi (India)

08:30 O-29 The Latin American Experience
Horacio Amaral, Santiago de Chile (Chile)

08:45 O-30 The Australian Experience
Tim Akhurst, Melbourne (Australia)

09:00 O-31 The Singapore Experience
Ajit Kumar Padhy, Singapore

09:15 O-32 The First American Experience
Eric H. Liu, Nashville (USA)

09:30 O-33 The Mexican Experience & Rest of the World
Enrique Estrada Lobato, Mexico City (Mexico)

09:45 Round Table with Session Lecturers

10:00 – 10:30 Coffee/Tea / Visit of Trade Exhibition / Poster Viewing

10:30 – 12:30 SCIENTIFIC SESSION 7
Novel Clinical Applications of Ga-68 Labeled Tracers
Chairpersons: Jaroslaw Cwikla, Warsaw (Poland); Irene Virgolini, Innsbruck (Austria)

10:30 O-34 Combined PET/MR Imaging for Ga-68 Labeled Tracers: A Case Study for Ga-68 DOTATOC in Meningioma Patients
Thomas Beyer, Tübingen (Germany)

10:45 O-35 PET/CT-Guided FNAC Biopsy (Metabolic FNAC/Biopsy) Using Automated Robotic Arm
Rakesh Kumar, New Delhi (India)

11:00 O-36 Ventilation/Perfusion Scans Using Ga-68 Labeled Tracers
Jörg Kotzerke, Dresden (Germany)

11:15 O-37 Radioguided Surgery in Neuroendocrine Tumors Using Ga-68 Labeled Somatostatin Analogues. A Pilot Study
Daniel Kämmerer, Bad Berka (Germany)

11:30 O-38 Somatostatin Receptor PET vs. its PET Competitors in the Diagnosis and Management Strategy of Patients with Neuroendocrine Tumors (NET), According to the Clinical Context and the Type of NET
Jean-Noël Talbot, Paris (France)

11:45 O-39 Glucagon-like Peptide-1 (GLP-1) Receptor-PET Imaging using Ga-68 Labeled GLP-1 Analogues
Damian Wild, Freiburg (Germany)
### Saturday, June 25, 2011 – Scientific Programme

#### Free Oral Papers

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00</td>
<td>O-40</td>
<td>Performance of DOTATOC PET/CT for the Detection of Insulinomas in Adults</td>
<td>Francoise Montravers, Paris (France)</td>
</tr>
<tr>
<td>12:10</td>
<td>O-41</td>
<td>Automated Synthesis of Ga-68 Exendin-4 for PET Imaging of Beta Cell Activity in Diabetes Mellitus</td>
<td>Mario De Decker, Fremantle (Australia)</td>
</tr>
<tr>
<td>12:20</td>
<td>O-42</td>
<td>Role of Ga-68 DOTA-SMS-R PET/CT in the Detection of Cardiac Metastases in Patients with Neuroendocrine Tumors</td>
<td>Vikas Prasad, Bad Berka (Germany)</td>
</tr>
<tr>
<td>12:30–14:00</td>
<td>Lunch</td>
<td>Lunch / Visit of Trade Exhibition / Poster Viewing</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>O-43</td>
<td>Milestones in Preclinical Applications and Future Developments Regarding Somatostatin Analogues</td>
<td>Marion de Jong, Rotterdam (The Netherlands)</td>
</tr>
<tr>
<td>14:15</td>
<td>O-44</td>
<td>PRRT with Lu-177([DOTA,Tyr3]Octreotate)</td>
<td>Dik Kwekkeboom, Rotterdam (The Netherlands)</td>
</tr>
<tr>
<td>14:25</td>
<td>O-45</td>
<td>The Swiss Experience</td>
<td>Jan Müller-Brand, Basel (Switzerland)</td>
</tr>
<tr>
<td>14:35</td>
<td>O-46</td>
<td>The Milano Experience</td>
<td>Lisa Bodei, Milano (Italy)</td>
</tr>
<tr>
<td>14:45</td>
<td>O-47</td>
<td>The German Experience</td>
<td>Dieter Hörsch, Bad Berka (Germany)</td>
</tr>
<tr>
<td>14:55</td>
<td>O-48</td>
<td>The Austrian Experience</td>
<td>Irene Virgolini, Innsbruck (Austria)</td>
</tr>
<tr>
<td>15:05</td>
<td>O-49</td>
<td>The UK Experience</td>
<td>John Buscombe, Cambridge (United Kingdom)</td>
</tr>
<tr>
<td>15:15</td>
<td>O-50</td>
<td>The Polish Experience</td>
<td>Jolanta Kunikowska, Warsaw (Poland)</td>
</tr>
<tr>
<td>15:35</td>
<td></td>
<td>Round Table with Session Lecturers</td>
<td></td>
</tr>
<tr>
<td>16:00–16:30</td>
<td>Coffee/Tea</td>
<td>Coffee/Tea / Visit of Trade Exhibition / Poster Viewing</td>
<td></td>
</tr>
</tbody>
</table>
Saturday, June 25, 2011 – Scientific Programme

16:30-18:40 SCIENTIFIC SESSION 9
Dosimetry and Radiation Protection
Chairpersons: Ignasi Carris, Barcelona (Spain); Michael Lassmann, Würzburg (Germany)

16:30 O-52 Bad Berka Dose Protocol (BBDP) – Results in 350 Patients with a Routinely Applicable Protocol for Dosimetry in PRRNT
Christiane Schuchardt, Bad Berka (Germany)

16:45 O-53 4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in Lu-177 Peptide Receptor Radionuclide Therapy
Kalevi Kairemo, Helsinki (Finland)

17:00 O-54 Dosimetry Assessment in Y-90 Peptide Targeted Radiotherapy: Y-90 and Y-90 Imaging
Stephan Walrand, Brussels (Belgium)

17:15 O-55 Renal Protection and Toxicity Related to Peptide Receptor Radionuclide Therapy (PRRNT) of Neuroendocrine Tumor
Vikas Prasad, Bad Berka (Germany)

17:30 O-56 Radiation Protection Issues in PRRNT and Results of the ORAMED Project
Arndt Rimpler, Berlin, Germany

17:45 O-57 Lu-177 Octreotate in GEP-NET: Outcome with Special Regard to Tumor Grade and Bone Metastases
Samer Ezziddin, Bonn (Germany)

Free Oral Papers
Chairpersons: Annare Ellmann, Cape Town (South Africa); Henry VanBrocklin, San Francisco (USA)

18:00 O-58 Does the Addition of Gelofusin in the Renal Protection of Patients Undergoing PRRNT Make a Difference?
Paul Maltby, Liverpool (United Kingdom)

18:10 O-59 The Possibility to Use Peptide Receptor Radionuclide Therapy as a Neoadjuvant Therapy in Patients with Inoperable Neuroendocrine Tumors (NETs)
Anna Sowa-Staszcak, Krakow (Poland)

18:20 O-60 Ga-68-DOTA-Somatostatin Analogues PET in Neuroendocrine Tumors: First Year Experience in Turkey
Emre Demirci, Istanbul (Turkey)

18:30 O-61 PET Lung Ventilation/Perfusion Imaging Using Gallium-68 Labeled Aerosol and Gallium-68 Labeled Macroaggregated Albumin (MAA)
Stephan-Johann Ament, Mainz (Germany)

18:40 End of sessions
19:00 Busses leaving from Zentralklinik Bad Berka to Rittergut München
19:30 Midsummer Night at Rittergut München
Sunday, June 26, 2011 – Scientific Programme

08:00 Registration

08:30–11:00 SCIENTIFIC Session 10
Current State of NET Therapy and PRRNT - Worldwide Experience
Chairpersons: Hans-Jürgen Biersack, Bonn (Germany); Ajit Kumar Padhy, Singapore

08:30 O-62 A Schema of Therapeutic Options for Neuroendocrine Tumors and the Value of Biomarkers
Thomas O’Dorisio, Iowa City (USA)

08:45 O-63 Systemic Therapy of Neuroendocrine Tumors in 2011 and in the Future
Edward M. Wolin, Los Angeles (USA)

09:00 O-64 Australian Experience of Radiopeptide Therapy of NET
J. Harvey Turner, Fremantle (Australia)

09:15 O-65 Neuroendocrine Tumor Treatment with Somatostatin Analog Peptides Labeled with Radionuclides: Latin-American Pioneer Experience
Horacio Amaral, Santiago de Chile (Chile)

09:30 O-66 PRRNT - The Indian Experience
Chandra Selvar Bal, New Delhi (India)

09:45 O-67 The US Experience in Providing PRRNT in Children, Adolescents and Adults
Sue O’Dorisio, Iowa City (USA)

10:00–11:30 Coffee/Tea/Visit of Trade Exhibition / Poster Viewing

Free Oral Papers
Chairpersons: John Buscombe, Cambridge (United Kingdom), Eric H. Liu, Nashville (USA)

10:00 O-68 Ga-68 DOTATOC vs. Ga-68 DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors
Thorsten D. Poeppel, Essen (Germany)

10:10 O-69 Comparison of Lesion Detection and Characterisation in Patients with Neuroendocrine Tumors Using DOTATOC-PET in Correlation with Contrast-enhanced MRI and Contrast-enhanced CT
Frederik L. Giesel, Heidelberg (Germany)

10:20 O-70 Diagnostic Impact of Ga-68 DOTA-TATE PET/CT Imaging in the Detection of Recurrent or Metastatic Medullary Thyroid Carcinoma and Elevated Calcitonin Levels
Anar Aliyev, Istanbul (Turkey)

10:30 O-71 Comparison of Ga-68 Somatostatin Analogues, F-18 DOPA and F-18 FDG PET/CT in Patients with Recurrent Medullary Thyroid Carcinoma: Also Ferrari does not Always Win!
Giovanni Treglia, Rome (Italy)

10:40 O-72 Comparison of Positron Emission Tomography with Ga-68 DOTATATE and F-18 FDG in Neuroendocrine Tumors
Sabire Yilmaz, Istanbul (Turkey)

10:50 O-73 PRRNT with Lu-177 DOTATATE for GEP-NET – Initial Results in Brazil
Aron J. Belfer, Sao Paulo (Brazil)

11:00–11:30 Coffee/Tea /Visit of Trade Exhibition / Poster Viewing
Sunday, June 26, 2011 – Scientific Programme

11:30 – 13:30 SCIENTIFIC SESSION 11
Novel Clinical Approaches for PRRNT of Neuroendocrine Tumors
Chairpersons: Carlos Libhaber, Cape Town (South Africa), Edward M. Wolin, Los Angeles (USA)

11:30 O-76 Effect of Peptide Receptor Radionuclide Therapy with TANDEM Isotopes-Y-90/Lu-177
DOTA-TATE in Patients with Disseminated Neuroendocrine Tumors
Jolanta Kunikowska, Warsaw (Poland)

11:45 O-75 PRRT Combined with Chemotherapy and Kinase Inhibitors
J. Harvey Turner, Fremantle (Australia)

12:00 O-76 TACE and SIRT Combined with PRRT or Intra-arterial PRRT
Alexander Petrovitch, Bad Berka (Germany)

12:15 O-77 Intra-arterial Bi-213-DOTATOC Alpha-Peptide Therapy in Patients with Neuroendocrine Tumors Refractory to Beta-radiation
Clemens Kratochwil, Heidelberg (Germany)

12:30 O-78 Intra-arterial PRRNT Using Y-90 DOTATATE – The Warsaw Experience
Jaroslaw Cwikla, Warsaw (Poland)

12:45 O-79 Engineered Bacteria for Cancer Theranostics
Jung-Joon Min, Chonnam (South Korea)

13:00 – 14:15 SCIENTIFIC SESSION 12
New Horizons & Future Developments
Chairpersons: Baljinder Singh, Chandigarh (India); Frank Rösch, Mainz (Germany)

13:00 O-80 Old and New Peptide Receptor Targets in Cancer: Future Directions
Jean-Claude Reubi, Bern (Switzerland)

13:15 O-81 Novel Targets for Peptide Receptor Based Imaging and Therapy
Wolfgang Weber, Freiburg (Germany)

14:00 Closing Lecture (Including Highlights)
Richard P. Baum, Bad Berka (Germany)

14:15 Closing Remarks

14:30 Farewell Barbeque
16:00 Busses leaving from Zentralklinik Bad Berka to Mainz (Post-Congress)
We would like to extend a special thanks to our industry sponsors and supporters.
### Lead Sponsors
- ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.
- GE Healthcare
- IBA Molecular Tracer
- Sanofi-Aventis Deutschland GmbH
- Scintomics GmbH
- Veenstra Instrumenten BV

### Bronze Sponsors
- Bio-Nucleonics, Inc.
- ChemMatech
- CIS bio GmbH
- IBA Molecular Tracer
- ImaginAb, Inc.
- Isotope Technologies Dresden GmbH
- Novartis Pharma GmbH
- OctreoPharm Sciences GmbH
- PerkinElmer
- Philips Technologie GmbH Innovative Technologies Research Laboratories
- PTW Freiburg & TEMA Sinergie
- Van Gahlen Nederland B.V.
- The Netherlands
- Van Gahlen GmbH Germany

### List of Exhibitors
- ABX-CRO advanced pharmaceutical services Forschungsgesellschaft m.b.H.
- GE Healthcare
- IBA Molecular Tracer
- Sanofi-Aventis Deutschland GmbH
- Scintomics GmbH
- Veenstra Instrumenten BV
ELENA
Isolator for GMP compliant handling of 68Ga-labeled radiopharmaceuticals

- In process quality control
- Suitable for all kinds of isotopes, ligands and peptides
- High yield
- Flexible, small sized module

In process quality control
Suitable for all kinds of isotopes,
Suitable for all kinds of isotopes,

- Air compressing station
- Quality control equipment
- Shipping containers
- Project & Validation Technical support
- Customized projects

RADIOCHEMISTRY PRODUCTS LINE
Active together

- Supply of radiopharmaceuticals and radiochemicals for research purposes
- GMP/GAMP5 compliant synthesis technology
- Support of clinical trials
- Full customer service

Eckert & Ziegler Radiopharma

Visit us at booth no. B5!

www.ezag.com/radiopharma